Physician profile
Mohan Mallam
NPI 1538161443
$2,951.17
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $436 · 2021: $70.04 · 2022: $2,157 · 2023: $255 · 2024: $33.81.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $288.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $288.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company Ltd. | $1,954.40 | 2022 | |
| Astrazeneca Pharmaceuticals Lp | $214.81 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $146.31 | 2021-2023 | |
| Alexion Pharmaceuticals, INC. | $132.63 | 2023 | Ultomiris |
| Boehringer Ingelheim Pharmaceuticals, INC. | $109.53 | 2019-2022 | |
| Acadia Pharmaceuticals INC | $90.02 | 2019 | |
| Sumitomo Pharma America, INC. | $69.28 | 2023 | Gemtesa |
| Philips North America LLC | $66.44 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $50.00 | 2019 | |
| Gilead Sciences, INC. | $33.81 | 2024 | |
| Amarin Pharma, INC. | $22.25 | 2021 | |
| Xeris Pharmaceuticals, INC. | $18.70 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $14.66 | 2019 | |
| Abbott Laboratories | $14.63 | 2021 | |
| Lilly USA, LLC | $13.70 | 2023 | Mounjaro |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohan Mallam listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.